The effect of Exenatide Therapy on inflammation, insulin requirement and weight in Obese Type 2 diabetes Mellitus patients on Insulin Shahid Mukhtar Banday.
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1 - TARIQUIDAR - Biochem Pharmacol,
Which difference should we target? Alberto Sobrero Ospedale San Martino IRCCS Genova, Italy.
Oncology Early Clinical Trials’ Designs and their Challenges Pamela N Munster, MD TICR 4-18-2012.
Adapted from the PMB through CTEP 2008 (revised 09/2014) NCORP-KC Guidelines for Investigational Drug Management.
The Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca Heart Failure (GISSI-HF) trial GISSI-HF Adapted from: Tavazzi et al.
Prof K M Prasanna Kumar Sr prof & Head-Endocrinology & Diabetes M S Ramaiah Medical college.
Which difference should we target?
FDG-PET/CT Technical Committee
GCP 101 or Why we do What we do the Way we do it Elaine Dempsey.
May 19-20, 2009. Quantitation, both single point and longitudinal*, of tumor metabolism via FDG-PET/CT that can be used practically and efficiently as.
1. Why do patients participate in clinical trials? 2. Overview of I-SPY2: Interacting with patients 3. Helping patients decide whether or not to participate.
